between the birthday parties, a computer malfunction, TradersAacause the Tim Sykes event it has been a bit hectic around here and I have not had much time to spend on the blog. That is all over now and I can get back into my old routine.
There were two glaring takeaways from both of the trader events I attended. I have mentioned this before in my workbook for traders but it was really emphasized for me over the two events.
1 >There is NO SILVER BULLET!
2 >You must learn your own personal strengths and weaknesses and develop a style that works for you!
I will be sharing more of what I took away from both events over the coming days and weeks as my routine normalizes and I find another venue to replace Ticker TV.
We have had a nice bounce in the markets but I remain skeptical. If you are sitting on some nice trading profits from the move over the last couple of days remember that cash is a viable position. Earnings season is on deck and that should provide us with a better picture of where the markets may be headed near term.
Stocks on my radar premarket
Bullish and may have lottos in play
Very Cautious may even present a short opportunity .
Applied DNA Sciences, Security Marketing Resource Announce Collaboration Agreement
Yes its thin its unknown and it has some really cool tech Full disclosure I am still sitting on some lottos I have been waiting for a significant pullback to reload but it has not happened Looks like it wants to take out 52 week highs> do not chase it but worth watching
Exelixis Resumes Trading +18% Following Announcement of Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma
- Mazor Robotics Reports First Renaissance System Installations at New York Metropolitan Area HospitalsBusiness Wire(Tue 5:30AM EDT)
Civeo CEO Dodson Buys 70,000 Shares @$1.54/Share -Form 4
Looking like it wants to break out of this range lots of shorts don't chase it can be a pop and flopper
Willbros Group Announces Sale of Professional Services Segment for $130M to TRC Companies
Novocure Announces FDA Approves Optune in Combination with Temozolomide for Treatment of Newly Diagnosed Glioblastoma